Arthritis denials in California external review
In the California DMHC record, independent physician reviewers decided 158 published external-review cases involving arthritisand overturned the plan’s denial in 56.3%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for arthritis
| Category | Decisions | Overturned |
|---|---|---|
| Arthritis Rx | 76 | 69.7% |
| Biologics | 26 | 57.7% |
| Viscosupp Injection | 8 | 87.5% |
| Anti-inflammatories | 8 | 37.5% |
| Pain Medication | 7 | 42.9% |
| Lab Work | 4 | 0% |
| Skin Treatment | 4 | 25% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 146 | 59.6% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 11 | 18.2% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/ Case Summary: The enrollee is requesting authorization and coverage for the requested medication, Orencia injections. The enrollee has rheumatoid arthritis, seropositive and centromere antibody positive. She started Humira and at a follow-up visit reported continued pain and loss of motion in a right finger. She also reported resolution of right wrist pain and knee pain. Her prior treatments include prednisone, which was tapered; methotrexate, for which higher doses were believed to be associated with hair loss; Humira, which she is no longer taking, and Enbrel. The enrollee’s rheumatologist requested prior authorization for Orencia, but in the interim, changed the enrollee’s medication to Enbrel. At a follow-up visit, improvement in foot pain was noted, but no significant change in her hand/finger symptoms.
Nature of Statutory Criteria/Case Summary: The patient is a 24-year-old female diagnosed with moderately to severely active seropositive (RF+/CCP+) rheumatoid arthritis. She was previously treated with methotrexate which failed to control her rheumatoid arthritis. The patient was noted to have a needle phobia. Due to the needle phobia the patient was not started on injectable or intravenous tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. The patient was subsequently placed on Rinvoq 15mg daily with significant improvement in her joint pain, joint swelling and joint stiffness. On 11/21/2022, the patient reported improvement in bilateral foot, hand, knee, ankle, wrist and shoulder pain.
Where the denial was upheld
Findings: The physician reviewer found that the patient has requested authorization and coverage for medically tailored meals. The Food is Medicine Coalition describes medically tailored meals as medically appropriate meals delivered to the homes of individuals living with complex, severe, or chronic illnesses who are too sick to shop or cook for themselves. These meals are supervised by registered dieticians and tailored toward the specific nutritional needs of eligible recipients. Nutrition and diabetes are intricately intertwined. Authors report that the foundation of medical nutrition therapy for type 2 diabetes is to achieve glucose, lipids, and blood pressure within the target range to prevent, delay, or manage microvascular and macrovascular complications.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for the medication Hydrocodone-Acetaminophen (Norco) 10-325mg tablets, quantity of 120 tablets per month, taken as one (1) tablet by mouth every 6 hours as needed.Standard therapy for rheumatoid arthritis/psoriatic arthritis includes the use of biologic drugs and DMARDs which are immunosuppressive therapies and carry the risk for infection. Due to a history of the left knee prosthetic joint infection, the patient has chosen to avoid biologic drugs and other DMARDs and is currently on hydrocodone-acetaminophen, which is an opiate, a controlled substance, to control chronic joint pain.Opioid pain medication use presents serious risks, including overdose and opioid use disorder.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving arthritis, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY